US FDA approves antibacterial Besivance for pink eye
This article was originally published in Scrip
Executive Summary
The US FDA has approved Bausch & Lomb's Besivance (besifloxacin ophthalmic suspension 0.6%; formerly referred to by the trade name Optura) as a treatment for bacterial conjunctivitis in patients aged one year and older.